Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Federal Trade Commission
US Department of Justice
Daiichi Sankyo
QuintilesIMS
Argus Health
Cantor Fitzgerald
UBS
Julphar
Accenture

Generated: February 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,691,336

« Back to Dashboard

Which drugs does patent 5,691,336 protect, and when does it expire?

Patent 5,691,336 protects EMEND and is included in one NDA.

This patent has thirty-six patent family members in twenty-seven countries.
Summary for Patent: 5,691,336
Title: Morpholine compounds are prodrugs useful as tachykinin receptor antagonists
Abstract:Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma, and emesis.
Inventor(s): Dorn; Conrad P. (Plainfield, NJ), Hale; Jeffrey J. (Westfield, NJ), Maccoss; Malcolm (Freehold, NJ), Mills; Sander G. (Woodbridge, NJ)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:08/525,870
Patent Claim Types:
see list of patent claims
Compound; Composition; Formulation; Use;

Drugs Protected by US Patent 5,691,336

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-001 Jan 25, 2008 DISCN Yes No ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-002 Nov 12, 2010 AP RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 5,691,336

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,512,570 Treatment of emesis with morpholine tachykinin receptor antagonists ➤ Sign Up
5,716,942 Treatment of migraine with morpholine tachykinin receptor antagonists ➤ Sign Up
5,780,467 Morpholine compounds are prodrugs useful as tachykinin receptor antagonists ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 5,691,336

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Germany 69528823 ➤ Sign Up
Israel 112778 ➤ Sign Up
Germany 122008000037 ➤ Sign Up
European Patent Office 0748320 ➤ Sign Up 08C0019 France ➤ Sign Up
European Patent Office 0748320 ➤ Sign Up SPC/GB08/021 United Kingdom ➤ Sign Up
Spain 2184794 ➤ Sign Up
Finland 963450 ➤ Sign Up
Croatia P950099 ➤ Sign Up
Hungary 9602409 ➤ Sign Up
Hungary T76324 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Federal Trade Commission
McKesson
Deloitte
Queensland Health
Farmers Insurance
UBS
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot